Pancreatic cancer drug daraxonrasib shrinks tumours in trial
A phase I/II trial of the pancreatic cancer drug daraxonrasib found tumours stopped growing in 90% of 61 patients with advanced disease, while about one in 12 saw cancer become undetectable on scans when the daily pill was paired with chemotherapy. Experts call it the biggest leap forward in decades, though doctors stress it is not yet a proven cure.
Key Takeaways
- Daraxonrasib plus chemotherapy halted tumour growth in 90% of 61 newly diagnosed patients with advanced, spread pancreatic cancer.
- Just over 60% saw tumours shrink or disappear; roughly 8% had no detectable disease on CT scans.
- At one year, 76.6% of trial patients were alive, versus a typical 40–45% on chemotherapy alone.
- Cancer Research UK called the results the biggest leap forward in decades; longer studies are still needed.
The findings, presented at the EORTC–NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, have sparked what researchers describe as massive hope for a disease that still has the lowest survival rate among common cancers in the UK. Coverage from BBC News and The Guardian underpins the figures below.
What did the daraxonrasib trial actually show?
All 61 participants had recently been diagnosed with advanced pancreatic cancer that had already spread. They received the daily pill daraxonrasib alongside chemotherapy (gemcitabine and nab-paclitaxel).
Tumours stopped growing in almost every patient. Just over 60% saw tumours shrink or vanish. In about one in 12 cases—roughly 8%—cancer became undetectable on CT imaging. Dr Wungki Park of Memorial Sloan Kettering Cancer Center, who presented the data, said the team is seeing deeper responses and a near doubling in the duration of disease control.
Patients were followed for about 18 months on average. Some did not see their cancer return in that window. A year after starting treatment, 76.6% were still alive, compared with the usual 40–45% survival at one year on chemotherapy alone.
Why does this matter for such a deadly cancer?
Pancreatic cancer is notoriously hard to treat. Half of people diagnosed die within three months, and only about 3% survive five years once the disease has spread to other organs. In Britain there are about 11,500 diagnoses and 10,200 deaths each year; in the United States it accounts for roughly 3% of cancers but about 8% of cancer deaths, killing around 53,000 people annually.
Michelle Mitchell, chief executive of Cancer Research UK, said the results raise real hope for one of the deadliest cancers, while noting survival remains very low and more trials are needed before NHS use can be assessed. Dr Sam Godfrey of the charity told the BBC the drug has found a way of “drugging the undruggable.”
For readers tracking major medical and public-interest stories, more coverage sits in our True Crime & Unsolved Mysteries hub.
Is the pancreatic cancer drug daraxonrasib a cure?
Doctors say no—not yet. It remains unclear how long the pill can keep disease at bay, and scans that look clear do not guarantee lasting remission. Daraxonrasib is a RAS/KRAS inhibitor already approved in the US; it locks onto mutations that drive most pancreatic tumours and may eventually help other cancers with similar mutations, including some lung and ovarian cases.
Prof Elena Garralda, chair of the Barcelona symposium, said the combined treatment could potentially improve overall survival and delay regrowth. Longer trials will decide whether any patients achieve durable remission—and for how long.